Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma.

Literature DB >> 24766470

Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma.

Penny Anders¹, Prasanna M Bhende, Michael Foote, Dirk P Dittmer, Steven I Park, Blossom Damania.

Abstract

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2014 PMID： 24766470 PMCID： PMC4258182 DOI： 10.3109/10428194.2014.917639

Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022

× No keyword cloud information.

17 in total

1. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy.

Authors: Kojo S J Elenitoba-Johnson; Stephen D Jenson; Robert T Abbott; Robert A Palais; Sandra D Bohling; Zhaosheng Lin; Sheryl Tripp; Paul J Shami; Lai Y Wang; Robert W Coupland; Rena Buckstein; Bayardo Perez-Ordonez; Sherrie L Perkins; Ian D Dube; Megan S Lim
Journal: Proc Natl Acad Sci U S A Date: 2003-05-19 Impact factor: 11.205

2. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death.

Authors: K P Lam; R Kühn; K Rajewsky
Journal: Cell Date: 1997-09-19 Impact factor: 41.582

3. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.

Authors: Patrick J Roberts; Jerry E Usary; David B Darr; Patrick M Dillon; Adam D Pfefferle; Martin C Whittle; James S Duncan; Soren M Johnson; Austin J Combest; Jian Jin; William C Zamboni; Gary L Johnson; Charles M Perou; Norman E Sharpless
Journal: Clin Cancer Res Date: 2012-08-07 Impact factor: 12.531

4. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Authors: Ajay K Gopal; Brad S Kahl; Sven de Vos; Nina D Wagner-Johnston; Stephen J Schuster; Wojciech J Jurczak; Ian W Flinn; Christopher R Flowers; Peter Martin; Andreas Viardot; Kristie A Blum; Andre H Goy; Andrew J Davies; Pier Luigi Zinzani; Martin Dreyling; Dave Johnson; Langdon L Miller; Leanne Holes; Daniel Li; Roger D Dansey; Wayne R Godfrey; Gilles A Salles
Journal: N Engl J Med Date: 2014-01-22 Impact factor: 91.245

5. The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma.

Authors: P M Bhende; S I Park; M S Lim; D P Dittmer; B Damania
Journal: Leukemia Date: 2010-08-12 Impact factor: 11.528

6. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.

Authors: Tammie C Yeh; Vivienne Marsh; Bryan A Bernat; Josh Ballard; Heidi Colwell; Ron J Evans; Janet Parry; Darin Smith; Barbara J Brandhuber; Stefan Gross; Allison Marlow; Brian Hurley; Joe Lyssikatos; Patrice A Lee; James D Winkler; Kevin Koch; Eli Wallace
Journal: Clin Cancer Res Date: 2007-03-01 Impact factor: 12.531

Review 7. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.

Authors: P J Roberts; C J Der
Journal: Oncogene Date: 2007-05-14 Impact factor: 9.867

8. Constitutive activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in B-cell lymphoproliferative disorders.

Authors: Toshie Ogasawara; Masako Yasuyama; Kiyotaka Kawauchi
Journal: Int J Hematol Date: 2003-05 Impact factor: 2.490

9. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Authors: Sauveur-Michel Maira; Frédéric Stauffer; Josef Brueggen; Pascal Furet; Christian Schnell; Christine Fritsch; Saskia Brachmann; Patrick Chène; Alain De Pover; Kevin Schoemaker; Doriano Fabbro; Daniela Gabriel; Marjo Simonen; Leon Murphy; Peter Finan; William Sellers; Carlos García-Echeverría
Journal: Mol Cancer Ther Date: 2008-07-07 Impact factor: 6.261

10. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.

Authors: Barry R Davies; Armelle Logie; Jennifer S McKay; Paul Martin; Samantha Steele; Richard Jenkins; Mark Cockerill; Sue Cartlidge; Paul D Smith
Journal: Mol Cancer Ther Date: 2007-08 Impact factor: 6.261

7 in total

Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma.

1. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy.

2. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death.

3. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.

4. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

5. The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma.

6. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.

Review 7. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.

8. Constitutive activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in B-cell lymphoproliferative disorders.

9. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

10. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.

Review 1. Animal models of tumorigenic herpesviruses--an update.

Review 2. Modulation of oncogenic signaling networks by Kaposi's sarcoma-associated herpesvirus.

Review 3. Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Associated Disease in the AIDS Patient: An Update.

Review 4. Cancers associated with human gammaherpesviruses.

Review 5. Recent advances in understanding Kaposi's sarcoma-associated herpesvirus.

Review 6. Systematic Review of the Potential of MicroRNAs in Diffuse Large B Cell Lymphoma.

Review 7. Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?